Short course of R-HyperCVAD/MTX/ARA-C followed by ASCT as first-line therapy in mantle cell lymphoma patients prolongs progression-free survival to more than 9 years
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI